We are live on
!
Find out more
CAM
Cormorant Asset Management Portfolio holdings
AUM
$1.95B
1-Year Est. Return
773.9%
This Fund
S&P 500
This Quarter
Est. Return
+0.54%
1 Year Est. Return
+773.9%
3 Year Est. Return
+3,976.92%
5 Year Est. Return
+17,750.67%
10 Year Est. Return
+592,782.78%
AUM
$2.46B
AUM Growth
-$483M
(-16%)
Cap. Flow
+$120M
Cap. Flow
% of AUM
4.86%
Top 10 Holdings %
Top 10 Hldgs %
47.28%
Holding
112
New
8
Increased
8
Reduced
35
Closed
24
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Erasca
ERAS
|
+$217M |
| 2 |
Immuneering
IMRX
|
+$60.5M |
| 3 |
Tango Therapeutics
TNGX
|
+$37.1M |
| 4 |
Cytokinetics
CYTK
|
+$29.4M |
| 5 |
Tyra Biosciences
TYRA
|
+$20.4M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Atea Pharmaceuticals
AVIR
|
+$41.1M |
| 2 |
Twist Bioscience
TWST
|
+$24.7M |
| 3 |
XLRN
Acceleron Pharma
XLRN
|
+$22M |
| 4 |
908 Devices
MASS
|
+$21.1M |
| 5 |
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
|
+$13.9M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 100% |
| 2 | Miscellaneous | 0% |
| 3 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
1
Erasca
ERAS
$5.37B
| $217M | 8.81% |
+10,505,550
| New | +$217M |
|
|
TPTX
2
DELISTED
Turning Point Therapeutics, Inc. Common Stock
TPTX
| $189M | 7.67% |
2,842,297
-194,745
| -6% | -$13.9M |
|
|
3
Atea Pharmaceuticals
AVIR
$413M
| $173M | 7.02% |
4,928,756
-1,482,599
| -23% | -$41.1M |
|
|
FMTX
4
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
| $109M | 4.45% |
4,720,495
-1,094
| -0% | -$25.9K |
|
5
Revolution Medicines
RVMD
$42B
| $86.5M | 3.52% |
3,144,700
-193,466
| -6% | -$5.63M |
|
6
Olema Pharmaceuticals
OLMA
$851M
| $84.7M | 3.44% |
3,073,485
| – | – |
|
7
BridgeBio Pharma
BBIO
$13.4B
| $82.9M | 3.37% |
1,768,909
-112,071
| -6% | -$6.01M |
|
8
Design Therapeutics
DSGN
$783M
| $78.8M | 3.2% |
5,364,850
-50,000
| -0.9% | -$831K |
|
9
ALX Oncology
ALXO
$243M
| $74.8M | 3.04% |
1,012,079
+122,625
| +14% | +$8.17M |
|
10
Monte Rosa Therapeutics
GLUE
$1.08B
| $68M | 2.76% |
3,102,199
-91,774
| -3% | -$2.63M |
|
|
11
Immuneering
IMRX
$288M
| $58.5M | 2.38% |
+2,252,626
| New | +$60.5M |
|
12
Edgewise Therapeutics
EWTX
$4.93B
| $56M | 2.27% |
3,370,914
+230,000
| +7% | +$4.16M |
|
|
BCAB
13
DELISTED
BIOATLA INC
BCAB
| $53.5M | 2.17% |
36,311
-2,723
| -7% | -$5.3M |
|
|
RNAM
14
DELISTED
Avidity Biosciences
RNAM
| $53.3M | 2.16% |
2,162,115
-66,552
| -3% | -$1.45M |
|
|
15
Tango Therapeutics
TNGX
$3.94B
| $48.8M | 1.98% |
3,899,185
+3,099,185
| +387% | +$37.1M |
|
|
RXDX
16
DELISTED
Prometheus Biosciences, Inc. Common Stock
RXDX
| $43.8M | 1.78% |
1,848,024
| – | – |
|
|
JBIO
17
Jade Biosciences
JBIO
$1.06B
| $42M | 1.71% |
58,020
| – | – |
|
18
Biomea Fusion
BMEA
$126M
| $38M | 1.54% |
3,170,872
| – | – |
|
|
19
Cytokinetics
CYTK
$9.65B
| $35.7M | 1.45% |
+1,000,000
| New | +$29.4M |
|
|
RAIN
20
DELISTED
Rain Oncology Inc. Common Stock
RAIN
| $34.8M | 1.41% |
2,326,660
-300,000
| -11% | -$5.12M |
|
|
AMAM
21
DELISTED
Ambrx Biopharma Inc
AMAM
| $33.1M | 1.34% |
2,486,386
| – | – |
|
|
VERV
22
DELISTED
Verve Therapeutics
VERV
| $32.7M | 1.33% |
709,224
| – | – |
|
23
Stoke Therapeutics
STOK
$1.8B
| $32.5M | 1.32% |
1,278,276
| – | – |
|
24
Tarsus Pharmaceuticals
TARS
$3.63B
| $31.1M | 1.27% |
1,444,831
-69,438
| -5% | -$1.72M |
|
|
APLS
25
DELISTED
Apellis Pharmaceuticals
APLS
| $30.5M | 1.24% |
925,000
+75,000
| +9% | +$4.21M |
|
Similar funds
AHC
FFS
GIP
SLF
BFPW
MSA
MAM
GF
Cormorant Asset Management's Q3 2021 Portfolio in Review
As of Q3 2021, Cormorant Asset Management held 112 positions worth $2.46B, down 16% from $2.94B the previous quarter. Its ten largest holdings account for 47% of the portfolio.
Cormorant Asset Management deployed $120M of net new capital in Q3 2021, opening 8 new positions and adding to 8 existing holdings. Its largest new stake was Erasca: 10,505,550 shares worth $217M.
By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 87% a quarter earlier, followed by Miscellaneous and Financials.
On the sell side, the largest reduction was Atea Pharmaceuticals, an estimated $41.1M trimmed.
- Cormorant Asset Management's largest Q3 2021 buy was Erasca: 10,505,550 shares worth $217M.
- Cormorant Asset Management added most to Tango Therapeutics in Q3 2021, an estimated $37.1M increase.
- Cormorant Asset Management's biggest Q3 2021 reduction was Atea Pharmaceuticals, cutting an estimated $41.1M.
- Cormorant Asset Management fully exited Twist Bioscience in Q3 2021, selling an estimated $24.7M.
- Cormorant Asset Management's ten largest holdings make up 47% of its $2.46B portfolio in Q3 2021.
- Cormorant Asset Management opened 8 new positions and closed 24 in Q3 2021.
- Cormorant Asset Management's portfolio value fell 16% quarter-over-quarter to $2.46B.
Based on Cormorant Asset Management's 13F filing for Q3 2021, filed 15 Nov 2021.